{"url_path":"/sec/sdgr/8-k/2026-06-29/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-29","source_url":"https://www.sec.gov/Archives/edgar/data/1490978/0001490978-26-000059-index.html","accession_number":"0001490978-26-000059","cik":"0001490978","ticker":"SDGR","issuer_name":"Schrodinger, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1490978/0001490978-26-000059-index.html","primary_entity_key":"0001490978","primary_entity_name":"Schrodinger, Inc."},"word_count":188,"has_tables":true,"body_markdown":"Item 7.01.    Regulation FD Disclosure.\n\nIn connection with the completion of Eli Lilly and Company’s acquisition of Ajax Therapeutics, Inc. (“Ajax”), a company co-founded by Schrödinger, Inc. (the “Company”), the Company received a cash payment of approximately $57 million. The Company is also eligible to receive additional cash payments upon the achievement by Ajax of specified clinical and regulatory milestones.\n\nThe information in this Current Report on Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\nSchrödinger, Inc.\n\nDate: June 29, 2026By:/s/ Yvonne Tran\n\nYvonne Tran\n\nChief Legal Officer and Corporate Secretary"}